A predictive model for HIV type 1 coreceptor selectivity

AIDS Research and Human Retroviruses

Volumn 29, Issue 10, 2013, Pages 1386-1394

  Kieslich, Chris A ^a   Shin, David ^a   De Victoria, Aliana López ^a   González Rivera, Gloria ^b   Morikis, Dimitrios ^a  

^a University of California Riverside   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120;

ARTICLE; BINDING KINETICS; CORECEPTOR SELECTIVITY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; STATISTICAL MODEL;

COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RECEPTORS, HIV; VIRUS ATTACHMENT;

EID: 84885089234     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0173     Document Type: Article

References (42)

1. Emini EA and Koff WC: AIDS/HIV. Developing an AIDS vaccine: Need, uncertainty, hope. Science 2004;304:1913-1914. (Pubitemid 38822172)
2. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280: 1884-1888. (Pubitemid 28299385)
3. Berger EA, Doms RW, Fenyo EM, et al.: A new classification for HIV-1. Nature 1998;391:240-240.
4. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700. (Pubitemid 29241137)
5. Broder CC and Jones-Trower A: Coreceptor use by primate lentiviruses. In: Human Retroviruses and AIDS 1999 (Kuiken CL et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1999, pp. 517-541.
6. Kuiken C, et al., eds.: HIV Sequence Compendium 2011, Vol LA-UR 10-03684. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2011.
7. Huang CC, Tang M, Zhang MY, et al.: Structure of a V3- containing HIV-1 gp120 core. Science 2005;310:1025-1028. (Pubitemid 41611916)
8. Huang CC, Lam SN, Acharya P, et al.: Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007;317:1930-1934. (Pubitemid 47509439)
9. López De Victoria A, Tamamis P, Kieslich CA, and Morikis D: Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops. PLoS One 2012;7:e49925.
10. Fouchier RAM, Groenink M, Kootstra NA, et al.: Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
11. López De Victoria A, Kieslich CA, Rizos AK, Krambovitis E, and Morikis D: Clustering of HIV-1 subtypes based on gp120 V3 loop electrostatic properties. BMC Biophys 2012;5:3.
12. Moore JP: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562. (Pubitemid 27390052)
13. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185: 621-628. (Pubitemid 27098147)
14. Maas JJJ, Gange SJ, Schuitemaker H, Coutinho RA, van Leeuwen R, and Margolick JB: Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000;14:1155-1161. (Pubitemid 30420658)
15. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997;3:1259-1265. (Pubitemid 27508828)
16. Doms RW and Moore JP: HIV-1 Coreceptor use: A molecular window into viral tropism. In: HIV Molecular Immunology Database 1997, Vol. IV (Korber B et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1997, pp. IV-25-36.
17. Koning F, van Rij R, and Schuitemaker H: Biological and molecular aspects of HIV-1 coreceptor usage. In: HIV Sequence Compendium 2002 (Kuiken C et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2002, pp. 24-42.
18. Lengauer T, Sander O, Sierra S, Thielen A, and Kaiser R: Predicting disease outcomes in the clinic. Nature Biotechnol 2008;26:612-613.
19. Jensen MA, Li FS, van't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to- X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376- 13388. (Pubitemid 37494331)
20. Schuitemaker H, van't Wout AB, and Lusso P: Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9(Suppl 1):S5.
21. Poon AFY, Swenson LC, Bunnik EM, et al.: Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data. PLoS Comput Biol 2012;8:e1002753.
22. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, and Paxton WA: N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001;276:13433-13441. The abbreviations of the amino acids of the glycosylation motif are N for asparagine (the glycosylation site), T for threonine, S for serine, and X for any amino acids except for proline.
23. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, and Zolla-Pazner S: Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007;23:415-426. (Pubitemid 46608562)
24. http://hiv.lanl.gov/
25. http://aids.gov/HIV-aids-basics/
26. http://geno2pheno.org/
27. http://indra.mullins.microbiol.washington.edu/webpssm/.
28. Pillai S, Good B, Richman D, and Corbeil J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19:145-149. (Pubitemid 36308052)
29. Low AJ, Dong W, Chan D, et al.: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21:F19-F26.
30. JensenMA, CoetzerM, van 'tWout AB,Morris L, andMullins JI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006;80:4698-4704.
31. Brumme ZL, Dong WWY, Yip B, et al.: Clinical and immunologicalimpact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004;18:F1-F9. (Pubitemid 38393456)
32. Masso M and Vaisman II: Accurate and efficient gp120 V3 loop structure based models for the determination of HIV-1 co-receptor usage. BMC Bioinform 2010;11:494.
33. Masso M and Vaisman II: AUTO-MUTE: Web-based tools for predicting stability changes in proteins due to single amino acid replacements. Protein Eng Des Sel 2010;23:683-687.
34. Prosperi MCF, Fanti I, Ulivi G, Micarelli A, De Luca A, and Zazzi M: Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. AIDS Res Hum Retroviruses 2009;25:305-314.
35. Sander O, Sing T, Sommer I, et al.: Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. Plos Comput Biol 2007;3:555-564.
36. Sing T, Low AJ, Beerenwinkel N, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007;12:1097-1106. (Pubitemid 350114990)
37. Xu S, Huang X, Xu H, and Zhang C: Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest. J Microbiol 2007;45:441-444.
38. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288:51-62. (Pubitemid 32846473)
39. Briggs DR, Tuffle DL, Sleasman JW, and Goodenow MM: Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000;14:2937-2939. (Pubitemid 32042758)
40. http://aidsmeds.com/list.shtml.
41. Lobritz MA, Ratcliff AN, and Arts EJ: HIV-1 entry, inhibitors, and resistance. Viruses-Basel 2010;2:1069-1105.
42. Tilton JC and Doms RW: Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010;85:91-100.